Back

Target dose of heart failure medications is associated with better mortality/morbidity: data from the Swedish Heart Failure Registry

29 June 2021 (08:33 - 08:45)
Organised by:
Congress Presentation Part of: Young Investigator Award: clinical research Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Daniele Rodolico

University of Pisa, Pisa (Italy)

3 More presentations in this session

Presentation thumbnail
Effect of SGLT2 inhibitors on diastolic function in patients with non-obstructive hypertrophic cardiomyopathy
Doctor M. Subramanian (Hyderabad, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis
Doctor V. De Marzo (Genoa, IT)
Abstract Slides Video
Presentation thumbnail
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
Doctor R. Rettl (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award: clinical research
Video

The Event

Event poster

Heart Failure 2021

29 June 2021 08:33 CET
You may be interested in
thumbnail
Congress Presentation
Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry
thumbnail
Congress Presentation
Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)
thumbnail
Congress Presentation
Efficacy and safety of rapid up-titration of medical therapies for heart failure by ischemic and non-ischemic etiologies: an analysis of STRONG-HF

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources